Pregnancy Clinical Trial
Official title:
Comparison of the ED95 Dose of 0.075% and 0.1% Bupivacaine for Labour Analgesia in Primigravida.
Local anaesthetics are highly toxic drugs. They can cause toxicity by an absolute overdose,
accidental injection in a blood vessel or slow absorption from the area of injection. The
risk of toxicity when performing regional anaesthesia can be reduced significantly by
injecting the optimal dose of local anaesthetic at the correct site.
To date most of the local anaesthetic dose finding studies for epidural labour analgesia has
focused on ED50 ( the dose effective in 50% of patients). The purpose of this research study
is to find out the ED95 dose (the dose effective in 95% of patients) of local anaesthetic
for epidural analgesia in labour.
The dose determined from this research trial will guide the anaesthetists to the optimal
starting dose of the local anaesthetics for epidural analgesia in labour. This would lead to
decreased chances of toxicity and will improve patient safety.
We aim to recruit a total of 100 pregnant patients in early labour (cervical dilatation ≤ 5
cm) requesting epidural analgesia to answer the research question based on the continual
reassessment method. Patients will be recruited according to well-defined criteria. They
will be fully informed about the study and have the choice of not participating or opting
out at any time during the study. It is not going to affect the kind of treatment they
receive. The experts in the field with full safety precautions will perform this study at St
James' Hospitals, Leeds.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | May 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - American Society of Anaesthesiologists (ASA) 1-3 patients - Primigravida (1st pregnancy) patients requesting epidural analgesia in early labour (= 5 cm cervical dilatation. Exclusion Criteria: - Primigravida (1st pregnancy) patients requesting epidural analgesia in late labour (> 5 cm cervical dilatation) - Multigravida patients ( = 2nd pregnancy) - ASA > 3 - Allergy to Bupivacaine - Unable to give written informed consent - BMI >35 - Abnormal blood coagulation profile - Patients taking any medication that are indicated in the Summary of Product Characteristics (SPC) as not recommended |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Leeds Teaching Hospitals NHS Trust | Leeds | West Yorkshire |
Lead Sponsor | Collaborator |
---|---|
University of Leeds | National Institute of Academic Anaesthesia (NIAA), UK, Obstetric Anaethetists' Association (OAA), UK |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effective dose in 95% of patients (ED95) dose of bupivacaine for a primigravida in early labour. | To find out the ED95 dose of bupivacaine 0.075% and 0.1% for epidural analgesia for a primigravida in early labour . | up to 30 minutes | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Completed |
NCT02523755 -
Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia
|
Phase 4 |